Key facts
- Centese’s last known valuation is $40.1M (Nov 2023).
- It has raised $30.5M across 3 recorded rounds; the latest was Seed Round ($250K) in May 2026.
- Notable investors include US National Science Foundation, New York Angels, Invest Nebraska, Barshop Ventures, Accuryn — 17 tracked in total.
- Centese has filed 2 Form Ds with the SEC since 2023, most recently May 2025 ($525K sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Centese
Funding rounds
3 roundsAbout Centese
Developer of advanced post-operative surgical drainage designed to address expensive and frequent complications in open-heart or open-lung surgery. The company's technology uses integrated sensors, algorithms, and a small battery-powered controller to monitor blood drainage and other fluids, enabling patients to recover quickly and providing clinicians with reliable data to make informed decisions.
- Sector
- Healthcare
- HQ
- Omaha, NE, United States
- Founded
- 2015
- Employees
- 17
- Website
- centese.com/
- Ownership
- Privately Held (backing)
Centese doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Centese shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Centese in its N-PORT filings yet. We sweep new filings monthly.